Inhibikase Therapeutics Inc. (IKT) Social Stream



Inhibikase Therapeutics Inc. (IKT): $0.85

-0.01 (-1.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IKT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 465

in industry

Inhibikase Therapeutics Inc (IKT) Price Targets From Analysts

Use the tables below to see what analysts covering Inhibikase Therapeutics Inc think about its future price and what recommendations they have for investors and traders.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2 $15 $12 $13.5 $2.12 536.79%

The Trend in the Analyst Price Target


IKT's average price target has moved down $0 over the prior 46 days.

Over the past 123 days, IKT's average upside potential has been 436.62%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-09-20 2 15 12 13.5 2.050 558.54%
2021-09-19 2 15 12 13.5 2.040 561.76%
2021-09-18 2 15 12 13.5 2.040 561.76%
2021-09-11 2 15 12 13.5 2.290 489.52%
2021-08-18 2 15 12 13.5 1.950 592.31%
2021-08-14 2 15 12 13.5 1.910 606.81%
2021-08-07 2 15 12 13.5 2.160 525%
2021-08-05 2 15 12 13.5 2.300 486.96%
2021-07-12 1 15 15 15.0 2.700 455.56%
2021-07-10 1 15 15 15.0 2.720 451.47%
2021-07-03 1 15 15 15.0 2.800 435.71%
2021-06-15 1 15 15 15.0 4.035 271.75%
2021-06-13 1 15 15 15.0 5.956 151.85%
2021-06-05 1 15 15 15.0 5.260 185.17%
2021-05-20 1 15 15 15.0 4.761 215.06%

IKT Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.5 0 2 0 0 0 2

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for IKT as an investment opportunity.

  • IKT has a higher upside potential (average analyst target price relative to current price) than 96.9% of all US stocks.
  • Inhibikase Therapeutics Inc's number of analysts covering the stock is greater than 13.07% of Healthcare stocks.
  • IKT has a higher average analyst price target than 25.34% of all US stocks.
  • Inhibikase Therapeutics Inc's variance in analysts' estimates is lower than 73.77% of Pharmaceutical Products stocks.

In the Pharmaceutical Products industry, AYTU, UNCY and VTVT are the three stocks most similar to Inhibikase Therapeutics Inc regarding the price target and analyst recommendation information presented here.

Is IKT a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5189 seconds.